Center Variation in Use of Preoperative Dual Antiplatelet Therapy and Platelet Function Testing at the Time of Coronary Artery Bypass Grafting in Maryland.

Abstract

BACKGROUND:

Patients presenting with acute coronary syndrome are administered a P2Y 12 inhibitor and aspirin before coronary catheterization to prevent further myocardial injury from thrombosis. Guidelines recommend a standard waiting period between the time patients are administered dual antiplatelet therapy (DAPT) and elective cardiac surgery. Since 25% to 30% of the population may be considered nonresponders to clopidogrel, platelet function testing can be utilized for timing of surgery and to assess bleeding risks. The extent to which a standard waiting period or platelet function testing is used across centers is not established, representing an important opportunity to standardize practice.

METHODS:

We conducted a retrospective cohort study from 2011 to 2020 using data from the Maryland Cardiac Surgical Quality Initiative, a consortium of all 10 hospitals in the state performing cardiac surgery. The proportion of patients administered DAPT within 5 days of surgery was examined by hospital over the time period. Mixed-effects multivariable logistic regressions were used to examine the association of preoperative DAPT with ischemic and bleeding outcomes. Centers were surveyed on use or nonuse of preoperative platelet function testing, and bleeding outcomes were compared.

RESULTS:

There was significant heterogeneity of preoperative DAPT usage across centers ranging from 2% to 54% ( P < .001). DAPT within 5 days of isolated coronary artery bypass grafting (CABG) was associated with higher odds of reoperation for bleeding (odds ratio [OR], 1.55; 95% confidence interval [CI], 1.19-2.01; P = .001), >2 units of red blood cells (RBCs) transfused (OR, 1.62; 95% CI, 1.44-1.81; P < .001), and >2 units of non-RBCs transfused (OR, 1.79; 95% CI, 1.60-2.00; P < .001). In the 5 hospitals using preoperative platelet function testing to guide timing of surgery, there were greater odds for DAPT within 5 days (OR, 1.33; 95% CI, 1.22-1.45; P < .001), fewer RBCs >2 units transfusions (22% vs 33%; P < .001), and non-RBCs >2 units (17% vs 28%; P < .001) transfusions within DAPT patients.

CONCLUSIONS:

There is significant variability in DAPT usage within 5 days of CABG between hospital centers. Preoperative platelet function testing may allow for earlier timing of surgery for those on DAPT without increased bleeding risks.

• Authors: Nadia B Hensley, Promise T Ariyo, Sari D Holmes, Marlene S Williams, Glenn Joseph Robert Whitman, Niv Ad, Thomas Stephen Metkus, Maryland Cardiac Surgical Quality Initiative
• Journal: Anesthesia and analgesia (Anesth Analg) Vol. 135 Issue 3 Pg. 567-575 (09 01 2022) ISSN: 1526-7598 [Electronic] United States
• PMID: 35426835 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 International Anesthesia Research Society.

Chemical References

• Platelet Aggregation Inhibitors
• Clopidogrel

Topics

• Clopidogrel (adverse effects)
• Coronary Artery Bypass (adverse effects)
• Drug Therapy, Combination
• Humans
• Maryland (epidemiology)
• Platelet Aggregation Inhibitors (therapeutic use)
• Retrospective Studies
• Treatment Outcome